Latest Insider Transactions at Edesa Biotech, Inc. (EDSA)
This section provides a real-time view of insider transactions for Edesa Biotech, Inc. (EDSA). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of Edesa Biotech, Inc. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of Edesa Biotech, Inc.'s insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Mar 14
2022
|
Michael J Brooks President |
BUY
Open market or private purchase
|
Direct |
1,250
+6.95%
|
$2,500
$2.79 P/Share
|
|
Mar 11
2022
|
Pardeep Nijhawan Chief Executive Officer |
BUY
Open market or private purchase
|
Direct |
7,000
+0.63%
|
$21,000
$3.12 P/Share
|
|
Mar 10
2022
|
Michael J Brooks President |
BUY
Open market or private purchase
|
Direct |
1,000
+6.06%
|
$3,000
$3.22 P/Share
|
|
Mar 09
2022
|
Pardeep Nijhawan Chief Executive Officer |
BUY
Open market or private purchase
|
Direct |
1,500
+0.27%
|
$4,500
$3.05 P/Share
|
|
Mar 08
2022
|
Michael J Brooks President |
BUY
Open market or private purchase
|
Direct |
1,250
+7.94%
|
$2,500
$2.9 P/Share
|
|
Mar 25
2021
|
Michael J Brooks President |
BUY
Open market or private purchase
|
Direct |
3,500
+20.91%
|
$17,500
$5.19 P/Share
|
|
Mar 25
2021
|
Pardeep Nijhawan Chief Executive Officer |
BUY
Open market or private purchase
|
Direct |
3,000
+0.55%
|
$15,000
$5.25 P/Share
|
|
Mar 24
2021
|
Pardeep Nijhawan Chief Executive Officer |
BUY
Open market or private purchase
|
Direct |
5,000
+0.91%
|
$25,000
$5.16 P/Share
|
|
Mar 24
2021
|
Michael J Brooks President |
BUY
Open market or private purchase
|
Direct |
4,500
+31.6%
|
$22,500
$5.08 P/Share
|
|
Feb 18
2021
|
Frank R. Oakes |
SELL
Open market or private sale
|
Direct |
6,165
-100.0%
|
$43,155
$7.25 P/Share
|
|
Feb 18
2021
|
Frank R. Oakes |
SELL
Open market or private sale
|
Indirect |
1,827
-100.0%
|
$12,789
$7.25 P/Share
|
|
Nov 09
2020
|
Lorin K Johnson |
BUY
Exercise of in-the-money or at-the-money derivatives securities
|
Direct |
4,262
+25.0%
|
$17,048
$4.0 P/Share
|
|
Nov 06
2020
|
Paul William Pay |
BUY
Exercise of in-the-money or at-the-money derivatives securities
|
Direct |
1,218
+25.0%
|
$4,872
$4.0 P/Share
|
|
Nov 06
2020
|
Kathi Niffenegger Chief Financial Officer |
BUY
Exercise of in-the-money or at-the-money derivatives securities
|
Indirect |
609
+25.0%
|
$2,436
$4.0 P/Share
|
|
Nov 06
2020
|
Michael J Brooks President |
BUY
Exercise of in-the-money or at-the-money derivatives securities
|
Direct |
914
+14.85%
|
$3,656
$4.0 P/Share
|
|
Nov 05
2020
|
Pardeep Nijhawan Chief Executive Officer |
BUY
Exercise of in-the-money or at-the-money derivatives securities
|
Indirect |
4,628
+0.22%
|
$18,512
$4.0 P/Share
|
|
Nov 05
2020
|
Carlo Sistilli Director |
BUY
Exercise of in-the-money or at-the-money derivatives securities
|
Indirect |
1,218
+25.0%
|
$4,872
$4.0 P/Share
|
|
Nov 02
2020
|
Velden Peter Van Der > 10% Shareholder |
BUY
Exercise of in-the-money or at-the-money derivatives securities
|
Indirect |
70,314
+3.28%
|
$281,256
$4.0 P/Share
|
|
Oct 06
2020
|
Frank R. Oakes |
BUY
Exercise of in-the-money or at-the-money derivatives securities
|
Indirect |
609
+25.0%
|
$2,436
$4.0 P/Share
|
|
Mar 29
2020
|
Pardeep Nijhawan Chief Executive Officer |
BUY
Open market or private purchase
|
Direct |
2,000
+0.36%
|
$10,000
$5.23 P/Share
|